Drug intelligence / Profile preview

micafungin + amphotericin B + itraconazole

Development stage: Preclinical
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination antifungal therapy consisting of micafungin (an echinocandin), amphotericin B (a polyene), and itraconazole (a triazole). Micafungin inhibits the synthesis of (1,3)-beta-D-glucan, an essential component of fungal cell walls. Amphotericin B binds to ergosterol in fungal cell membranes, creating pores that lead to cell death. Itraconazole inhibits fungal cytochrome P450-dependent enzymes, preventing the synthesis of ergosterol. This combination has been studied for treating acute invasive aspergillosis, with micafungin showing potential synergistic activity with amphotericin B.

Targets

FKS (1,3-beta-D-glucan synthase component FKS1)ErgosterolCYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on micafungin + amphotericin B + itraconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on micafungin + amphotericin B + itraconazole.

Explore the full profile